Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and repor

来源 :World Journal of Gastroenterology | 被引量 : 0次 | 上传用户:zuoluo1314
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Selective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However, coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP), which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S. Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis of gastrointestinal tract, such as the esophagus, stomach and colorectum, and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors. Selective cyclooxygenase (COX) -2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However, coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP) , which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the US Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis o f gastrointestinal tract, such as the esophagus, stomach and colorectum, and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors.
其他文献
目的探讨经腹腹膜前腹腔镜疝修补术(TAPP)及开放式无张力疝修补术在治疗腹股沟复发疝中的效果。方法回顾性分析56例单侧腹股沟复发疝患者的临床资料,其中行TAPP 26例(腹腔镜组),开放式无张力疝修补术30例(开放组),比较两组手术时间、术中出血量、术后疼痛评分、术后住院时间、术后并发症、住院费用以及术后复发等。结果两组患者均顺利完成手术。腹腔镜组术中出血量、术后疼痛评分、术后住院时间明显优于开放
目的评价CO2激光辅助深层巩膜切除术治疗开角型青光眼的效果。方法回顾性分析2016年1月至2017年3月开角型青光眼连续病例61例(76眼)的临床资料,随机分为观察组和对照组。观察组进行CO2激光辅助深层巩膜切除术,共27例(32眼),其中男20例(23眼),女7例(9眼),平均年龄(47.22±11.15)岁。对照组进行传统小梁切除术,共34例(44眼),其中男23例(32眼),女11例(12眼
期刊
期刊
目的评价尿苷二磷酸葡萄糖醛酸转移酶1A1(UGT1A1)*6基因多态性与伊立替康致3~4级中性粒细胞减少和腹泻的关系。 方法检索PubMed、Science Direct、Wiley Online Library、Web of Science、中国知网、万方数据库和维普中文科技期刊数据库(建库至2015年1月15日),收集研究UGT1A1*6基因多态性与伊立替康致3~4级中性粒细胞减少和腹泻关系的
目的:考察稀红通络提取液的精制工艺.方法:以奇任醇保留率、干膏得率为考察指标,比较水提醇沉法、超滤法和ZTC1+1-Ⅱ天然澄清剂吸附法在豨红通络提取液精制中的效果,并且采取
目的分析椎旁神经阻滞联合臭氧注射治疗腰椎间盘突出症的临床疗效。方法选取腰椎间盘突出症患者84例,其中采用椎旁神经阻滞治疗42例(对照组),采用椎旁神经阻滞联合臭氧注射治疗42例(观察组),均每周1次,共4周,于治疗后6个月随访。比较两组疼痛视觉模拟评分(VAS)变化、临床疗效、不良反应等。结果两组治疗后和随访时VAS均明显低于治疗前[观察组:(2.95 ± 1.31)和(2.87±1.35)分比(
目的检测晚期胰腺癌患者溶质载体家族1号(SLC29A1)基因1288位点单核苷酸多态性(SNP)的序列,探讨其与吉西他滨化疗不良反应及预后的关系。方法抽取患者外周血,提取血中DNA,应用PCR法扩增含SLC29A1基因1288位点的片段,采用DNA测序法检测1288位点的SNP序列。根据检测结果,将患者分为SLC29A1基因1288位点突变型组和野生型组,比较两组患者的临床资料、吉西他滨化疗的不良
目的观察小梁切除术前玻璃体内注射康柏西普联合广泛视网膜光凝治疗新生血管性青光眼(NVG)的远期疗效。方法回顾性分析2014年1月至2014年12月新生血管性青光眼30例(30眼)的资料所有患者行玻璃体内注射康柏西普,待新生血管消退后行小梁切除术联合广泛视网膜光凝术。随访30个月。观察治疗后眼压、视力、虹膜新生血管消退情况及并发症。结果27眼(90.00%)虹膜表面新生血管于玻璃体内注药后3~7d完
期刊